Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
Authors:
- Richard de BoerRBRichard de Boer
- Christopher D HartCHChristopher D Hart
Open Access
- 1 January 2013
- journal article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 6, 1-7
Abstract
Peer reviewed article authored by (Hart CD, De Boer RH). Read article or submit your manuscript for publishing.Keywords
This publication has 29 references indexed in Scilit:
- Genetic controls and cellular behaviors in branching morphogenesis of the renal collecting systemWIREs Developmental Biology, 2012
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet CancerCancer Research, 2011
- Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath TumorsClinical Cancer Research, 2011
- Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid CarcinomaThyroid®, 2010
- RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancerExpert Review of Anticancer Therapy, 2008
- AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor XenograftsCancer Research, 2006
- Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitorsOncogene, 2004
- Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the ThyroidEndocrine Pathology, 2000
- Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer.1995